ATE184271T1 - Analoge von benzamid, zur verwendung als parp(adp-ribosyltransferase, adprt) dns- reparaturenzyminhibitoren - Google Patents

Analoge von benzamid, zur verwendung als parp(adp-ribosyltransferase, adprt) dns- reparaturenzyminhibitoren

Info

Publication number
ATE184271T1
ATE184271T1 AT95910653T AT95910653T ATE184271T1 AT E184271 T1 ATE184271 T1 AT E184271T1 AT 95910653 T AT95910653 T AT 95910653T AT 95910653 T AT95910653 T AT 95910653T AT E184271 T1 ATE184271 T1 AT E184271T1
Authority
AT
Austria
Prior art keywords
adp
parp
dna repair
compounds
cymine
Prior art date
Application number
AT95910653T
Other languages
English (en)
Inventor
Roger John Griffin
Alan Hilary Calvert
Nicola Jane Curtin
David Richard Newell
Bernard Thomas Golding
Original Assignee
Univ Newcastle Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Newcastle Ventures Ltd filed Critical Univ Newcastle Ventures Ltd
Application granted granted Critical
Publication of ATE184271T1 publication Critical patent/ATE184271T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/16—Compounds containing azido groups with azido groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
AT95910653T 1994-03-09 1995-03-09 Analoge von benzamid, zur verwendung als parp(adp-ribosyltransferase, adprt) dns- reparaturenzyminhibitoren ATE184271T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9404485A GB9404485D0 (en) 1994-03-09 1994-03-09 Benzamide analogues

Publications (1)

Publication Number Publication Date
ATE184271T1 true ATE184271T1 (de) 1999-09-15

Family

ID=10751492

Family Applications (3)

Application Number Title Priority Date Filing Date
AT98202102T ATE210651T1 (de) 1994-03-09 1995-03-09 Benzamidanaloga zur verwendung als parp- (adp- ribosyltransferase, adprt) dns-reparaturenzym inhibitoren
AT98202103T ATE231494T1 (de) 1994-03-09 1995-03-09 Chinazoline als chemotherapeutika
AT95910653T ATE184271T1 (de) 1994-03-09 1995-03-09 Analoge von benzamid, zur verwendung als parp(adp-ribosyltransferase, adprt) dns- reparaturenzyminhibitoren

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT98202102T ATE210651T1 (de) 1994-03-09 1995-03-09 Benzamidanaloga zur verwendung als parp- (adp- ribosyltransferase, adprt) dns-reparaturenzym inhibitoren
AT98202103T ATE231494T1 (de) 1994-03-09 1995-03-09 Chinazoline als chemotherapeutika

Country Status (13)

Country Link
US (3) US5756510A (de)
EP (3) EP0879820B1 (de)
JP (1) JPH09510704A (de)
CN (1) CN1081624C (de)
AT (3) ATE210651T1 (de)
CA (1) CA2184747C (de)
DE (3) DE69512036T2 (de)
DK (2) DK0879820T3 (de)
ES (2) ES2135707T3 (de)
GB (1) GB9404485D0 (de)
GR (1) GR3031886T3 (de)
PT (1) PT879820E (de)
WO (1) WO1995024379A1 (de)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372770B1 (en) 1994-10-12 2002-04-16 Euro-Celtique, S.A. Benzoxazoles
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
AU1743997A (en) * 1996-12-20 1998-07-17 Geron Corporation Poly(adp-ribose) polymerase inhibitors to treat diseases associated with cellular senescence
GB9702701D0 (en) * 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
DE19726824C1 (de) * 1997-06-24 1999-03-04 Deutsches Krebsforsch Verfahren zur Identifizierung kanzerogener Agenzien
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
AU9298198A (en) * 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US20020028813A1 (en) * 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US20020022636A1 (en) * 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
WO1999011622A1 (en) * 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6235748B1 (en) 1997-09-03 2001-05-22 Guilford Pharmaceuticals Inc. Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6346536B1 (en) 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
FR2776291B1 (fr) * 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6380193B1 (en) 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
US6395749B1 (en) 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
EP1077944A1 (de) * 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Carboxamide verbindungen,methode und zusammensetzungen zur hemmung derparp-aktivitaet
AU9298798A (en) * 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
CA2352964C (en) 1998-12-01 2006-10-17 University Of Kentucky Research Foundation A method for enhancing protective cellular responses to genotoxic stress in skin
US6201020B1 (en) 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
PT1140936E (pt) 1999-01-11 2004-06-30 Agouron Pharma Inibidores triciclicos de poli(adp-ribose) polimerases
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6444676B1 (en) 1999-12-20 2002-09-03 Iok-Hou Pang Use of PARP inhibitors in the treatment of glaucoma
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
SI2223922T1 (sl) * 2000-04-25 2016-04-29 Icos Corporation Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US6723733B2 (en) 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
WO2001091796A2 (en) 2000-06-01 2001-12-06 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
WO2002006240A1 (en) 2000-07-13 2002-01-24 Guilford Pharmaceuticals Inc. Substituted 4,9-dihydrocyclopenta[imn] phenanthridine-5-ones, derivatives thereof and their uses
GB0017508D0 (en) * 2000-07-17 2000-08-30 Novartis Ag Antimicrobials
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
US6660858B2 (en) 2001-03-28 2003-12-09 Lion Bioscience Ag 2-aminobenzoxazole derivatives and combinatorial libraries thereof
MXPA04001353A (es) * 2001-08-15 2004-10-27 Icos Corp 2h-ftalazin-1-onas y metodos para su uso.
WO2003043995A1 (en) 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
AUPR975601A0 (en) * 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
JP2005529076A (ja) * 2002-02-15 2005-09-29 サイトキネティクス・インコーポレーテッド キナゾリノンの合成
CA2482806A1 (en) 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Phthalazinone derivatives
MXPA04011074A (es) * 2002-05-09 2005-06-08 Cytokinetics Inc Compuestos de pirimidinona, composiciones y metodos.
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
EP1513820A4 (de) * 2002-05-23 2006-09-13 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
AU2003236527A1 (en) * 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
US7211580B2 (en) * 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
JP2005536553A (ja) * 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2004034972A2 (en) * 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
EP2210892A3 (de) 2002-10-04 2010-10-27 Prana Biotechnology Limited Neurologisch aktive Verbindungen
AU2002951868A0 (en) * 2002-10-04 2002-10-24 Prana Biotechnology Limited Compound i
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1611137A1 (de) * 2003-03-31 2006-01-04 Pfizer Inc. Salze von tricyclischen poly(adp-ribose)polymerasen
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
US20050197327A1 (en) * 2003-11-03 2005-09-08 Gustave Bergnes Compounds, compositions, and methods
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
CA2546002C (en) 2003-11-20 2012-09-18 Janssen Pharmaceutica N.V. 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
CA2546300C (en) 2003-11-20 2012-10-02 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
SG150548A1 (en) 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
US7439254B2 (en) * 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
HUE030950T2 (en) 2004-05-13 2017-06-28 Icos Corp Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol
CN1980913B (zh) 2004-06-30 2011-12-14 詹森药业有限公司 作为parp抑制剂的喹唑啉二酮衍生物
MXPA06014543A (es) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de quinazolinona como inhibidores de la poli(adp-ribosa)polimerasa-i.
ES2563954T3 (es) 2004-06-30 2016-03-16 Janssen Pharmaceutica Nv Derivados de ftalazina como inhibidores de PARP
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
ATE540675T1 (de) 2005-04-01 2012-01-15 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
KR20080031266A (ko) * 2005-06-10 2008-04-08 바이파 사이언스 인코포레이티드 Ｐａｒｐ 조절제 및 암의 치료
SG164368A1 (en) * 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CA2629376C (en) * 2005-11-14 2015-06-09 Centre National De La Recherche Scientifique - Cnrs Inhibitors of parp activity and uses thereof
US8560350B2 (en) * 2005-11-22 2013-10-15 Robert J. Nadai Method, system and computer program product for generating an electronic bill having optimized insurance claim items
US20140039920A1 (en) * 2005-11-22 2014-02-06 Robert J. Nadai Methodology, system and computer program product for generating electronic insurance claims or bills, having optimized insurance claim items in order to maximize reimbursement and to facilitate approval of the claim(s) upon first submission to the insurance carrier
KR20100110396A (ko) 2006-04-14 2010-10-12 프라나 바이오테크놀로지 리미티드 연령 관련 황반 변성（에이엠디）의 치료 방법
WO2007137000A2 (en) * 2006-05-16 2007-11-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Combination cancer chemotherapy
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2655257A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
EP2041087A1 (de) * 2006-06-15 2009-04-01 Kudos Pharmaceuticals Limited 2-oxybenzamidderivate ls parp-inhibitoren
WO2008030891A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
CA2662517A1 (en) * 2006-09-05 2008-03-13 Jerome Moore Treatment of cancer
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
PL2109608T3 (pl) 2007-01-10 2011-08-31 Msd Italia Srl Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
WO2008107478A1 (en) 2007-03-08 2008-09-12 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
JP5525447B2 (ja) 2007-10-26 2014-06-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのキノリノン誘導体
US7732491B2 (en) * 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
CN101918003A (zh) * 2007-11-12 2010-12-15 彼帕科学公司 单独使用parp抑制剂或与抗肿瘤剂组合治疗子宫癌和卵巢癌
MX2010006154A (es) * 2007-12-07 2010-09-24 Bipar Sciences Inc Tratamiento del cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de la poli-adp-ribosa-polimerasa.
NZ586675A (en) 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
CN101999002A (zh) * 2008-02-04 2011-03-30 彼帕科学公司 诊断和治疗parp-介导的疾病的方法
CN101998959B (zh) * 2008-02-06 2013-08-28 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
CN101531638B (zh) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
WO2009118382A1 (en) 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors
JP5464609B2 (ja) 2008-03-27 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チューブリン重合阻害剤としてのキナゾリノン誘導体
CN101628913B (zh) * 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
EA020783B1 (ru) 2008-10-07 2015-01-30 Астразенека Юк Лимитед Фармацевтическая композиция, содержащая 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-он и коповидон
CA3092449A1 (en) 2008-11-13 2010-05-20 Gilead Calistoga Llc Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
WO2010082813A1 (en) 2009-01-13 2010-07-22 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Method of treating cancer
WO2010083220A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzoxazole inhibitors of poly(adp-ribose)polymerase
EP2411391A1 (de) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomere von 2-purinyl-3-tolylchinazolinonderivaten und anwendungsverfahren
ES2548253T3 (es) 2009-04-20 2015-10-15 Gilead Calistoga Llc Métodos para el tratamiento de tumores sólidos
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
CN102382097B (zh) * 2010-09-03 2013-08-07 中国科学院上海药物研究所 芳甲胺类衍生物及其药物组合物、制备方法和用途
AU2011298423B2 (en) 2010-09-03 2015-11-05 Bayer Intellectual Property Gmbh Substituted fused pyrimidinones and dihydropyrimidinones
WO2013064083A1 (en) * 2011-11-01 2013-05-10 Impact Therapeutics, Inc. 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
CN102531946A (zh) * 2012-01-05 2012-07-04 山东大学 3-甲氧基苯甲酰胺衍生物及其制备方法与应用
PE20141792A1 (es) 2012-03-05 2014-12-07 Gilead Calistoga Llc Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
JP2015532650A (ja) 2012-09-05 2015-11-12 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 非生物的植物ストレスに対する活性物質としての置換された２−アミドベンズイミダゾール類、２−アミドベンゾオキサゾール類および２−アミドベンゾチアゾール類またはそれらの塩の使用
KR102200628B1 (ko) * 2012-09-26 2021-01-08 메르크 파텐트 게엠베하 Ｐａｒｐ 억제제로서의 퀴나졸리논 유도체
EP3083623A1 (de) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphe formen eines hydrochloridsalzes aus (s)-2-(9h-purin-6-ylamino)propyl)-5-fluor-3-phenylchinazolin-4 (3h)-on
CA2934531C (en) 2013-12-20 2020-02-25 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
EP3097088A4 (de) * 2014-01-23 2017-10-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Icariin-derivate
CN106459005A (zh) 2014-06-13 2017-02-22 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
US11261466B2 (en) 2015-03-02 2022-03-01 Sinai Health System Homologous recombination factors
EP3325623B3 (de) 2015-07-23 2021-01-20 Institut Curie Verwendung einer kombination aus dbait-molekül und parp-inhibitoren zur behandlung von krebs
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
WO2018085359A1 (en) 2016-11-02 2018-05-11 Immunogen, Inc. Combination treatment with antibody-drug conjugates and parp inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
AU2018260094A1 (en) 2017-04-28 2019-11-07 Akribes Biomedical Gmbh A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
EP3765613A1 (de) 2018-03-13 2021-01-20 Onxeo Dbait-molekül gegen erworbene resistenz in der behandlung von krebs
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US26565A (en) * 1859-12-27 Improved register for railroad-cars
US3169129A (en) * 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) 1966-03-02 1969-04-29 Table iii
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
US4323503A (en) * 1976-08-04 1982-04-06 Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France Substituted 2,3-alkylene di (oxy) benzamides and derivatives
US4281127A (en) * 1979-07-09 1981-07-28 Hoffmann-La Roche Inc. Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives
EP0054132B1 (de) * 1980-12-12 1984-10-10 Dr. Karl Thomae GmbH Neue Pyrimidinone, ihre Herstellung und Arzneimittel mit einem Gehalt an diesen Stoffen
DE3202898A1 (de) 1982-01-29 1983-08-11 Geze Gmbh, 7250 Leonberg Antriebseinheit fuer fluegel, insbesondere schiebefluegel von tueren o.dgl.
DE3220898A1 (de) * 1982-06-03 1983-12-08 Dr. Karl Thomae Gmbh, 7950 Biberach Verfahren zur herstellung von pyrimidinonen und ihren saeureadditionssalzen
US4499303A (en) * 1983-09-27 1985-02-12 Research Corporation Antihyperlipidemic N-benzoylsulfamates, N-benzylsulfamates and benzylsulfonamides
US5032617A (en) * 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
DE3690206T1 (de) * 1985-05-03 1987-09-17
JPS62258368A (ja) * 1986-03-10 1987-11-10 Agency Of Ind Science & Technol キナゾリン−４−オンの製造方法
EG18188A (en) * 1986-05-01 1992-09-30 Pfizer Ltd Process for preparation anti-arhythmia agents
ZA885929B (en) * 1987-08-25 1989-04-26 Oxi Gene Inc Agents for use in tumor or cancer cell killing therapy
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
US5254692A (en) * 1990-04-06 1993-10-19 Bayer Aktiengesellschaft 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines
GB9011833D0 (en) * 1990-05-25 1990-07-18 Collins Mary K L Inhibition of viral infection
US5238942A (en) * 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
DE4142366A1 (de) * 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0609211A4 (de) * 1991-10-22 1995-02-01 Octamer Inc Adenosin-diphosphoribose-polymerase bindende nitrosoaromatische verbindungen als antitumorale und antiretrovirale wirkstoffe.
US5464871A (en) * 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5223539A (en) * 1991-11-22 1993-06-29 G. D. Searle & Co. N,n-di-alkyl(phenoxy)benzamide derivatives
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5587384A (en) * 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity

Also Published As

Publication number Publication date
EP0897915A1 (de) 1999-02-24
GB9404485D0 (en) 1994-04-20
ATE231494T1 (de) 2003-02-15
EP0897915B1 (de) 2003-01-22
ATE210651T1 (de) 2001-12-15
DE69524641D1 (de) 2002-01-24
US6015827A (en) 2000-01-18
DK0879820T3 (da) 2002-04-02
GR3031886T3 (en) 2000-02-29
AU693167B2 (en) 1998-06-25
WO1995024379A1 (en) 1995-09-14
DK0749415T3 (da) 2000-03-20
ES2169472T3 (es) 2002-07-01
CA2184747A1 (en) 1995-09-14
CN1081624C (zh) 2002-03-27
EP0749415B1 (de) 1999-09-08
EP0879820B1 (de) 2001-12-12
DE69512036D1 (de) 1999-10-14
AU1856595A (en) 1995-09-25
EP0879820A1 (de) 1998-11-25
DE69529482D1 (de) 2003-02-27
DE69529482T2 (de) 2003-06-12
US6316455B1 (en) 2001-11-13
US5756510A (en) 1998-05-26
DE69524641T2 (de) 2002-08-14
EP0749415A1 (de) 1996-12-27
DE69512036T2 (de) 1999-12-30
ES2135707T3 (es) 1999-11-01
JPH09510704A (ja) 1997-10-28
PT879820E (pt) 2002-06-28
CN1143358A (zh) 1997-02-19
CA2184747C (en) 2003-10-14

Similar Documents

Publication Publication Date Title
ATE184271T1 (de) Analoge von benzamid, zur verwendung als parp(adp-ribosyltransferase, adprt) dns- reparaturenzyminhibitoren
EA199800184A1 (ru) Соединение бензимидазола
BG106586A (en) Pyrazolopyramidines as therapeutic agents
FI885569A (fi) Vattenloesliga kamptothecinanaloger.
NZ324887A (en) Piperazine and piperidine compounds with analgesic effect
BR9812699A (pt) Derivados de benzamidina
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
BR0010220A (pt) Compostos de pirimidinona
UA35557C2 (uk) Похідні 1,2,4-оксадіазолілфеноксіалкілізоксазолу, що мають противірусну активність та фармацевтична композиція на їх основі
NZ313185A (en) 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
BR0004535A (pt) Compostos, e, uso dos mesmos.
DK0960111T3 (da) Morphinderivat med analgesisk aktivitet
DK144685A (da) Substituerede benzopyraner, fremgangsmaader til fremstilling deraf samt deres anvendelse i laegemidler
MY129935A (en) Dihydropyridine derivatives useful in antitumor therapy
AU3626895A (en) Quinazolinone pharmaceuticals and use thereof
DE69619259D1 (de) Amidin- und isothioharnstoffderivate als inhibitoren der stickstoffoxid-synthase
HK1047431A1 (en) Benzamidine derivatives
CA2352592A1 (en) Quinazolinone compounds
CY2582B2 (en) New imidazopyridines and oxazolopyridines
ES8707939A1 (es) Procedimiento para preparar derivados de n-carboxialquil-2--oxo-3-diaril-5,6-triazinas
GB9723905D0 (en) Heterocyclic compounds having MMP and TNF inhibitory activity
MX9801680A (es) Derivado de fenil pirimidina opticamente activo como agente analgesico.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee